Clinical Trials Logo

Clinical Trial Summary

To summarise, the peripheral neurological complications experienced by patients with primary Sjögren's syndrome are particularly bothersome since they are common and often result in significant disability related to pain or motor impairment. There is currently no standard treatment for these patients. As these neuropathies are caused by an immune system dysfunction, which is related to a variety of different pathogenic mechanisms, the use of immunosuppressant or immunomodulator drugs is often justified. With the exception of the vascularitis-related multiplex mononeuropathies, other pSS-related neuropathies could be suitable candidates for IV Ig treatment.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT03700138
Study type Interventional
Source University Hospital, Strasbourg, France
Contact Jacques-Eric GOTTENBERG, MD
Phone 03 88 12 79 53
Email jacques-eric.gottenberg@chru-strabourg.fr
Status Recruiting
Phase Phase 3
Start date June 19, 2019
Completion date July 2026